Thursday, September 3, 2015

4 stocks to watch: EFOI, LPCN, CEB, CRTO

As the market got hit hard on Tuesday, there are some broken charts, but still some outperformers as well. Here are two longs and two shorts to watch.
Energy Focus
Energy Focus Inc.Apr 15May 15Jun 15Jul 15Aug 15Sep 15Source: MarketWatch
US:EFOI
$0$5$10$15$20$25$30
Energy Focus Inc. EFOI,  has had stellar action, up another 46 cents to 22.36 on Tuesday in the face of a falling market. It has been consolidating beautifully right near resistance. If it gets through here, it could see the high 20.00s. Short-term support is around 18.50-18.75. The target is 26.75.

Lipocine
Lipocine Inc.Apr 15May 15Jun 15Jul 15Aug 15Sep 15Source: MarketWatch
US:LPCN
$5.0$7.5$10.0$12.5$15.0$17.5$20.0
Lipocine Inc. LPCN, also doing very well. Even though it did get a sharp pullback recently, it held the trendline and lateral price support, as well as the 50-day moving average and bounced nicely. On Tuesday, it was up 87 cents, or 6%, to 15.59, on 437,300 shares. Volume wasn't great, but if it can get through the 15.90-16.00 zone, it could test the recent spike highs up around 17.83. If it gets through that, then look for 20.00-21.00 as the next target.

CEB
CEB Inc.Apr 15May 15Jun 15Jul 15Aug 15Sep 15Source: MarketWatch
US:CEB
$65$70$75$80$85$90$95
On the short side, CEB Inc. CEB,  has broken down out of several bear wedges recently. On Tuesday, it got clobbered for 2.69 to 68.93. It looks like it's going to test the January lows and lateral support around 66.75-67.00 as early as Wednesday morning. Through that it could see 64.00, even 59.00-60.00 if it fills the gap.

Criteo SA
Criteo S.A. ADRApr 15May 15Jun 15Jul 15Aug 15Sep 15Source: MarketWatch
US:CRTO
$30$40$50$60$20
Criteo SA CRTO,  had a big drop last week and then rallied back to resistance, but right now is rolling over again. On Tuesday, it failed to hold lateral support, dropping another 2.08 to 37.13. Unless it bounces on Wednesday, it could come down to the low 30.00s.

Please share this article

No comments:

Post a Comment